Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance
NCT00618072Phase 2Completed
- Sponsor
- New York Medical College
- Start
- Jan 2008
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metformin and rosiglitazone in insulin resistance (IR), obesity and hyperinsulinemia (3 arms), sponsored by New York Medical College. Primary endpoint: Fasting Insulin at 6 months. Started Jan 2008; status: completed.
02
Drugs
metforminrosiglitazone
03
Conditions
insulin resistance (IR)obesityhyperinsulinemia
Beyond the preview
Go deeper on NCT00618072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00618072.